Classen Immunotherapies, Inc. v. Shionogi, Inc.

by Robins Kaplan LLP
Contact

Case Name: Classen Immunotherapies, Inc. v. Shionogi, Inc., Civ. No. 13-921-RWT, 2014 U.S. Dist. LEXIS 10642 (D. Md. Jan. 29, 2014) (Titus, J.)

Drug Product and Patent(s)-in-Suit: Computer algorithm and method of product safety; U.S. Patents Nos. 7,984,069 (“the ’069 patent”) and 7,653,639 (“the ’639 patent”)

Nature of the Case and Issue(s) Presented: The issue presented was whether Classen filed a complaint with sufficient factual allegations to survive a motion to dismiss for failure to state a claim under Fed. R. Civ. P. 12(b)(6). Classen is the assignee of the ’069  and ’639 patents. The two patents claim methods for generating, organizing, and commercializing “adverse event” information associated with a product or device. They describe a database management methodology for evaluating the efficacy of a therapeutic method and identifying its associated side effects. Classen filed its complaint against defendants Shionogi and Merz Pharmaceuticals, LLC on March 27, 2013. On May 31, 2013, defendants filed a motion to dismiss for failure to state a claim upon which relief could be based. The court found in favor of defendants.

Why Shionogi Prevailed:  Shionogi based its motion to dismiss on the safe-harbor provision of 35 U.S.C. § 271(e)(1). Previous district court decisions had determined that the § 271(e)(1) safe-harbor provision constitutes an affirmative defense. But the court noted that despite the general rule that an affirmative defense may not serve as a basis for dismissal under Rule 12(b)(6), the court may consider affirmative defenses on a motion to dismiss where they are clear from the face of the complaint. The court concluded that Classen’s complaint clearly implicated the safe harbor provision of § 271(e)(1), as it asserted that defendants infringed the ’069 and ’639 patents by improperly commercializing information required to be disclosed pursuant to the federal pharmaceutical regulatory process described in § 271(e)(1). Accordingly, the court concluded that analysis under Rule 12(b)(6) was appropriate.

The court next addressed the function of the safe-harbor provision, which was enacted to shield drug manufacturers from patent-infringement liability for using patented inventions in activities that are reasonably related to the development and submission of information pursuant to the federal regulatation of pharmaceuticals. Activities carried out to satisfy FDA requirements fall within the safe harbor. According to the court, the key inquiry for safe-harbor purposes is whether the defendant's actions were carried out to satisfy the FDA’s requirements. Because the text of § 271(e)(1) is not restricted to pre-approval activities, § 271(e)(1) also applies to post-FDA approval activities falling within its scope.

In light of the safe-harbor provision, Classen’s claims of infringement were clearly foreclosed. The processes disclosed in the ’069 and ’639 patents were inherently tied to a regulatory-approval process, as they required that the “novel essential adverse event” described in each patent be “one regulated by a regulatory agency requiring disclosure of the event in a package insert or data sheet accompanying the product or device.” Classen argued that its infringement allegations were not barred by the safe-harbor provision because the patents included claims that were commercialization steps which were not used to develop or submit information to the FDA. This argument was based on the theory that the safe harbor expires after FDA approval is obtained. The court disagreed, finding that recent case law indicated that there is no pre/post FDA approval dichotomy under the safe-harbor provision.

The court went on to address several additional shortcomings related to the sufficiency of Classen’s allegations. First, the claims of the asserted patents required steps that occurred prior to the issuance of the patents in suit. In order to overcome this defect, Classen relied on intervening rights under § 154(d). The court concluded that the statutory language of each section did not support Classen’s argument: § 271 applies to actions taken “during the term of the patent,” while § 154(d) applies to actions “during the period beginning on the date of publication of the application…and ending on the date the patent is issued.” Classen failed to cite to any case law supporting its novel argument that the two sections could be combined in order to create a cause of action for infringement. Secondly, the court found that Classen’s infringement allegations failed under § 154(d) because the published ’069 and ’639 patent applications were not substantially identical to the patents that ultimately issued. When a published patent application’s claims are amended such that their scope is changed, the patent is no longer “substantially identical” to its application. Both the ’069 and ’639 patents underwent enough changes from application to issuance that § 154(d) no longer applied. Finally, the court found that the allegations directed toward co-defendant Merz Pharmaceuticals, LLC had to be dismissed because Merz was alleged to have committed only one step of the patented process: Merz was accused of activities related to “commercialization.” Thus, Classen failed to allege that Merz had undertaken all of the steps required to infringe its patented methods.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robins Kaplan LLP | Attorney Advertising

Written by:

Robins Kaplan LLP
Contact
more
less

Robins Kaplan LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.